首页> 美国卫生研究院文献>Journal of the Royal Society Interface >Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization
【2h】

Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

机译:个性化医学时代的甲亢:数学优化的兴起

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thyroid over-activity or hyperthyroidism constitutes a significant morbidity afflicting the world. The current medical practice of dose titration of anti-thyroid drug (ATD) treatment for hyperthyroidism is relatively archaic, being based on arbitrary and time-consuming trending of thyroid function that requires multiple clinic monitoring visits before an optimal dose is found. This prompts a re-examination into more deterministic and efficient treatment approaches in the present personalized medicine era. Our research project seeks to develop a personalized medicine model that facilitates optimal drug dosing via the titration regimen. We analysed 49 patients' data consisting of drug dosage, time period and serum free thyroxine (FT4). Ordinary differential equation modelling was applied to describe the dynamic behaviour of FT4 concentration. With each patient's data, an optimization model was developed to determine parameters of synthesis rate, decay rate and IC50. We derived the closed-form time- and dose-dependent solution which allowed explicit estimates of personalized predicted FT4. Our equation system involving time, drug dosage and FT4 can be solved for any variable provided the values of the other two are known. Compared against actual FT4 data within a tolerance, we demonstrated the feasibility of predicting the FT4 subsequent to any prescribed dose of ATD with favourable accuracy using the initial three to five patient-visits' data respectively. This proposed mathematical model may assist clinicians in rapid determination of optimal ATD doses within allowable prescription limits to achieve any desired FT4 within a specified treatment period to accelerate the attainment of euthyroid targets.
机译:甲状腺过度活跃或甲状腺功能亢进症构成困扰世界的重大疾病。针对甲状腺功能亢进症的抗甲状腺药物(ATD)治疗剂量滴定的当前医学实践是相对陈旧的,它基于甲状腺功能的任意且耗时的趋势,需要在找到最佳剂量之前进行多次临床监护。在当前的个性化医学时代,这促使人们重新审视更加确定性和有效的治疗方法。我们的研究项目旨在开发个性化的药物模型,以通过滴定方案促进最佳药物剂量。我们分析了49位患者的数据,包括药物剂量,时间段和血清游离甲状腺素(FT4)。用常微分方程建模来描述FT4浓度的动态行为。利用每个患者的数据,开发了一个优化模型来确定合成速率,衰减速率和IC50的参数。我们得出了封闭形式的时间和剂量依赖的解决方案,该解决方案允许对个性化预测的FT4进行显式估计。我们的方程系统涉及时间,药物剂量和FT4,只要其他两个变量的值已知,就可以求解。与在容差范围内的实际FT4数据相比,我们证明了分别使用最初的三到五个患者就诊数据,以任何有利剂量准确预测ATD规定剂量后的FT4的可行性。该提出的数学模型可以帮助临床医生在允许的处方限制内快速确定最佳ATD剂量,以在指定的治疗期内实现任何所需的FT4,以加速实现甲状腺功能正常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号